Mitotech S.A, a clinical-stage biotechnology company, announced that its Chief Scientific Officer, Dr Maxim Skulachev, will give a presentation at the Targeting Mitochondria 2023 conference, taking place in October 2023 in Berlin, Germany. The conference is an annual event attracting academia and industry experts in mitochondria biology. Dr Skulachev’s talk is titled “Advances in the Development of Mitochondria-Targeted Pharmaceuticals”. The talk will highlight Mitotech’s progress in drug development for a variety of therapeutic areas such as Multiple Sclerosis, Obesity and NASH, including recent results from animal efficacy models. Targeting Mitochondria 2023 is an International in-person conference and will take place October 11-13, 2023. Dr Skulachev’s talk is scheduled for October 12 at 9.20 a.m. CET.
About Mitotech S.A.
Mitotech S.A. is a Luxembourg-based late clinical stage biotechnology company developing drugs to treat the mitochondrial oxidative stress underlying metabolic and neurodegenerative disorders. Mitotech’s products are based on novel small molecules that inhibit ferroptosis within mitochondria.